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functional status was class III with recent worsening of dyspnea and apparent leg edema. Transthoracic echocardiography
revealed right ventricular enlargement with mean pulmonary artery pressure of 42mmHg. After PTPA, he was complicated with
postoperative reperfusion pulmonary edema, and noninvasive positive pressure ventilation (NPPV) was applied immediately.
Hypoxemia was successfully treated with 15 days of NPPV. Although mean pulmonary artery pressure was unchanged, his brain
natriuretic peptide level decreased from preoperative 390.3 to postoperative 44.3pg/dL. In addition, total pulmonary resistance
decreased from preoperative 18 to postoperative 9.6wood unit·m2. The patient was discharged on day 25 with SpO2 of 95%
on 5L/min of oxygen inhalation. Because pulmonary edema is a postsurgical life-threatening complication following PTPA,
application of NPPV should be considered.
1.Introduction
Pulmonary hypertension is classiﬁed into 5 categories ac-
cording to speciﬁc therapeutic interventions directed at the
underlying causes [1]. Chronic thromboembolic pulmonary
hypertension (CTEPH) is classiﬁed into WHO group 4,
in which surgical procedures are recommended in selected
patients [2]. We experienced a patient with CTEPH, who
underwent percutaneous transluminal pulmonary angio-
plasty (PTPA). This patient was complicated with postoper-
ative pulmonary edema, and noninvasive positive pressure
ventilation (NPPV) was applied for the postoperative 15
days.
2.Case
A 69-year-old man with CTEPH was scheduled for PTPA;
a new treatement strategy originally reported in 2001 [3]i n
USA and now developing in Japan [4]. On medical checkup
at 52 years of age, he was pointed out to have cardiomegaly.
At 54, he noticed exercisintolerance and dyspnea and was
diagnosed to have pulmonary hypertension with cardiac
catheterization and multiple stenoses and occlusions of his
peripheral pulmonary arteries by pulmonary angiography.
Pulmonary artery endarterectomy was not indicated because
most of the lesions were not located at the proximal
pulmonary arteries. He started to take warfarin, ticlopidine
hydrochloride, and nifedipine. At 59, he had dyspnea at rest
and was diagnosed to have protein S deﬁciency and CTEPH.
His symptom developed gradually, and amblatory oxygen
inhalation therapy (3L/min) and oral intake of sildenaﬁl
citrate were started at 68 year, and PTPA was scheduled at
69.
On admission to our hospital, the patient’s New York
Heart Association functional status was class III with recent2 Case Reports in Anesthesiology
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Figure 1: Chest X-ray and representative computed tomography image obtained on day 1. The patient had localized consolidation on his
left lower lobe, suggesting postsurgical pulmonary edema in the dilated segment.
worsening of dyspnea and apparent leg edema. His SpO2
was 94% with 3L/min of oxygen inhalation, cardiothoracic
ratio on chest X-ray was 60%, and his brain natriuretic
peptide (BNP) level was 390.3pg/dL. Transthoracic echocar-
diography revealed right ventricular enlargement with mean
pulmonary artery pressure of 42mmHg. The diameter of the
inferior vena cava (IVC) was 20/18mm.
InitialPTPAwasperformedforhisleftpulmonaryartery.
Seven peripheral regions of his left pulmonary artery was
dilated by the balloon. At the end of the procedure, his
pulmonary artery pressure was 91/27mmHg, and he was
admitted to the intensive care unit. On admission to the
intensive care unit (day 0), his SpO2 was 95% with 40% of
oxygen inhalation with no complain of dyspnea. On day 1,
his chest X-ray and computed tomography revealed localized
consolidation on his left lower lobe (Figure 1). On day 2,
consolidation on chest X-ray developed in accordance with
his complication of dyspnea. Because his SpO2 decreased
to 70% with 10L/min of oxygen inhalation using reservoir
mask, NPPV was applied.
The initial setting of NPPV was CPAP mode with
10mmHg inhaling 100% of oxygen. Applying NPPV, SpO2
increased up to 90%. CPAP was gradually decreased and was
5mmHg on day 5. NPPV was ﬁnally discontinued on day 16.
Although mean pulmonary artery pressure was unchanged
asassessedbypostoperative cardiaccatheterization,hisbrain
natriuretic peptide level decreased from preoperative 390.3
to postoperative 44.3pg/dL. In addition, total pulmonary
resistance decreased from preoperative 18 to postoperative
9.6woodunit·m2.Thepatientwasdischargedonday25with
SpO2 of 95% on 5L/min of oxygen inhalation and NYHA
class II status.
3. Discussion
For patients suﬀering from CTEPH, pulmonary thromboen-
darterectomy (PTE) is increasingly successful [2]. Evidence-
based clinical practice guidelines have recommended that
patients with suspected CTEPH should be referred to
centers experienced in the procedure for consideration of
PTE [1]. However, not all patients with CTEPH have
surgically accessible disease. In patients who are deemed
nonsurgical or high-risk surgical candidates, there are 3
potentialoptions:medicaltherapy,lungtransplantation,and
balloon pulmonary angioplasty (PTPA), a catheterization-
based interventional management strategy [5].
Feinstein et al. reported 18 patients without surgical
potential who underwent PTPA [6]. In their report, the
average New York Heart Association class improved from
3.3 to 1.8 after an average of 36 months of followup.
However, 11 patients suﬀered from postsurgical pulmonary
edemadeﬁnedasradiographicopacityinthedilatedsegment
and worsening hypoxemia, 4 at the time of catheterization
and 7 during the subsequent 48 hours. All patients with
reperfusion pulmonary edema were managed with diuretics
and oxygen. Three patients required mechanical ventilation
and 1 patient died 1 week after PTPA.
In the case presented, the patient started to suﬀer from
postsurgical pulmonary edema in the dilated segmenton on
day 1. To avoid mechanical ventilation for worsening hypox-
emia, NPPV was immediately applied, and oxygenation
was improved. After 16 days of NPPV treatment, his right
ventricular dysfunction improved as evidenced by decreased
BNP concentration [7].
In summary, we experienced a patient with postsur-
gical, reperfusion pulmonary edema following PTPA. The
patient developed severe hypoxemia and was successfully
treated with 15 days of NPPV. Because pulmonary edema
is a postsurgical life-threatening complication following
PTPA, application of NPPV should be immediately con-
sidered.
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